1 completed, 1 withdrawn. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow PSA Progression: new trials by email Literature Review of PSA Progression trials Research Report on PSA Progression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer Decitabine, Enzalutamide - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 1 / Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2021-04-15 | 2022-10-05 | |
| Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer Enzalutamide, Venetoclax - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 1 | Completed | Roswell Park Cancer Institute | 10 | 2019-08-02 | 2023-10-16 |
Genital Diseases (2) · Genital Diseases, Male (2) · Genital Neoplasms, Male (2) · Male Urogenital Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Prostatic Diseases (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2)
enzalutamide (2) · Decitabine (1) · Injections (1) · venetoclax (1)
Roswell Park Cancer Institute (2)
United States (2)
Gurkamal Chatta (2)